PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models

被引：0

作者：

Kenkel, Justin A. ^{[1
]}

Gadkari, Rishali ^{[1
]}

Ho, Po Y. ^{[1
]}

Blum, Lisa K. ^{[1
]}

Kudirka, Romas ^{[1
]}

Henning, Karla A. ^{[1
]}

Mallet, William G. ^{[1
]}

Melrose, Jennifer E. ^{[1
]}

Sarma, Ganapathy ^{[1
]}

Chapin, Steven J. ^{[1
]}

Zhou, Matthew ^{[1
]}

Deol, Suprit ^{[1
]}

Kreder, Cindy ^{[1
]}

Shen, Yuyi ^{[1
]}

Hug, Bruce ^{[1
]}

Anand, Puneet ^{[1
]}

Lee, Arthur ^{[1
]}

Li, Hai ^{[1
]}

Ackerman, Shelley E. ^{[1
]}

Safina, Brian S. ^{[1
]}

Dornan, David ^{[1
]}

Alonso, Michael N. ^{[1
]}

Kowanetz, Marcin ^{[1
]}

机构：

[1] Bolt Biotherapeut, Redwood City, CA USA

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4252

引用

页数：1

共 50 条

[1] PD-L1-TARGETED ISAC COMBINES MYELOID CELL ACTIVATION, IMMUNE-CHECKPOINT INHIBITION AND ADCP TO IMPROVE ANTI-TUMOR EFFICACY OVER ANTI-PD-L1 ANTIBODIES IN PRECLINICAL MODELS
Kenkel, Justin
Gadkari, Rishali
Henning, Karla
Kudirka, Romas
Mallet, William
Ho, Po
Sarma, Ganapathy
Chapin, Steven
Bogaert, Liz
Melrose, Jennifer
Zhou, Matthew
Deol, Suprit
Kreder, Cindy
Shen, Yuyi
Anand, Puneet
Lee, Arthur
Li, Hai
Ackerman, Shelley
Safina, Brian
Dornan, David
Alonso, Michael
Kowanetz, Marcin
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A817 - A817
[2] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J.
Page, D. B.
Li, B. T.
Connell, L. C.
Schindler, K.
Lacouture, M. E.
Postow, M. A.
Wolchok, J. D.
ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
[3] Anti-tumor and immune effects of olaparib plus /- anti-PD-L1 in preclinical BRCA1mut tumor models
Staniszewska, Anna
Armenia, Joshua
King, Matthew
Michaloglou, Chrysiis
Singh, Maneesh
San Martin, Maryann
Wilson, Zena
Proia, Theresa
Delpuech, Oona
O'Connor, Mark
Leo, Elisabetta
Valge-Archer, Viia
CANCER RESEARCH, 2020, 80 (16)
[4] Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models
Wang, Sarah
Sun, Kaiming
Xiao, Yonghong
Feng, Bin
Mikule, Keith
Ramaswamy, Sridhar
Hanke, Jeffrey
Wang, Jing
CANCER RESEARCH, 2018, 78 (13)
[5] ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma
Henry, Kelly E.
Mack, Kyeara N.
Nagle, Veronica L.
Cornejo, Mike
Michel, Adam O.
Fox, Ian L.
Davydova, Maria
Dilling, Thomas R.
Pillarsetty, Nagavarakishore
Lewis, Jason S.
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 2026 - 2034
[6] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies (vol 26, pg 2375, 2015)
Naidoo, J.
Page, D. B.
Li, B. T.
Connell, L. C.
Schindler, K.
Lacouture, M. E.
Postow, M. A.
Wolchok, J. D.
ANNALS OF ONCOLOGY, 2016, 27 (07) : 1362 - 1362
[7] Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
Maohua Li
Rongqing Zhao
Jianxin Chen
Wenzhi Tian
Chenxi Xia
Xudong Liu
Yingzi Li
Song Li
Hunter Sun
Tong Shen
Wenlin Ren
Le Sun
Scientific Reports, 11
[8] Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
Li, Maohua
Zhao, Rongqing
Chen, Jianxin
Tian, Wenzhi
Xia, Chenxi
Liu, Xudong
Li, Yingzi
Li, Song
Sun, Hunter
Shen, Tong
Ren, Wenlin
Sun, Le
SCIENTIFIC REPORTS, 2021, 11 (01)
[9] Combination of ANTI-PD-1/ANTI-PD-L1 Antibodies With the Distinct Character Exerts Preferable Anti-Tumor Immune Cycle in a Murine Neuroblastoma Model
Inoue, S.
Horiuchi, Y.
Setoyama, Y.
Takeuchi, Y.
Murakami, T.
Odaka, A.
PEDIATRIC BLOOD & CANCER, 2020, 67 : S157 - S157
[10] The gastrointestinal microbiome and its composition are critical for antitumor efficacy of immune checkpoint inhibition by anti-PD-L1
Cuiffo, Benjamin G.
Parello, Caitlin S.
Ritchie, Chelsea
Pedrick, Katie
Kury, Alexandra
Costa, Catarina
Van Dam, Brett
Jung, Jonathan
Lyng, Gregory D.
Sonis, Stephen T.
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →